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ABSTRACT
The kissing-loop complex that initiates dimeri-
zation of genomic RNA is crucial for Human
Immunodeficiency Virus Type 1 (HIV-1) replication.
We showed that owing to its strong similitude
with the bacterial ribosomal A site it can be tar-
geted by aminoglycosides. Here, we present its
crystal structure in complex with neamine, ribo-
stamycin, neomycin and lividomycin. These struc-
tures explain the specificity for 4,5-disubstituted
2-deoxystreptamine (DOS) derivatives and for sub-
type A and subtype F kissing-loop complexes, and
provide a strong basis for rational drug design. As
a consequence of the different topologies of the
kissing-loop complex and the A site, these aminogly-
cosides establish more contacts with HIV-1 RNA than
with 16S RNA. Together with biochemical experi-
ments, they showed that while rings I, II and III confer
binding specificity, rings IV and V are important for
affinity. Binding of neomycin, paromomycin and livi-
domycinstronglystabilizedthekissing-loopcomplex
by bridging the two HIV-1 RNA molecules.
Furthermore, in situ footprinting showed that the
dimerization initiation site (DIS) of HIV-1 genomic
RNA could be targeted by these aminoglycosides
in infected cells and virions, demonstrating its
accessibility.
INTRODUCTION
Dimerization of genomic RNA is ubiquitous among
retroviruses (1,2). It is beneﬁcial for reverse transcription,
including recombination, and is intricately linked to encapsi-
dation of the genomic RNA and possibly to the morphogen-
esis of the mature viral core [for review, see (3)]. It was also
proposed to indirectly regulate translation of the gag gene (3).
In Human Immunodeﬁciency Virus Type 1 (HIV-1), the
dimerization initiation site (DIS) of the genomic RNA is a
stem–loop (SL1) motif characterized by a 6 nt self-
complementary sequence in a 9 nt loop. The same self-
complementary sequence is found in all HIV subtypes, except
in subtypes B and D, and ﬂanking nucleotides are mostly
purines (Figure 1a and b) (3). Mutations in SL1 are character-
ized by unstable and/or aberrant RNA dimers; they affect
RNA packaging and reverse transcription, and result in
strongly diminished infectivity (up to 100 000-fold) (4–7).
RNA dimerization is initiated by intermolecular base pair-
ing of the DIS self-complementary sequence (8–11), and the
resulting ‘kissing-loop’ complex is stabilized by the ﬂanking
unpaired nucleotides (12–14) (Figure 1c). In vitro studies on
short RNA fragments showed that the isolated SL1 could also
adopt a more stable extended duplex structure [(3) and refer-
ences therein]. Inside the virions, the initial poorly stable
dimer is maturated into a more stable dimer upon processing
of the Gag precursor (15). However, there is no evidence that
this mature dimer corresponds to the extended dimer formed
in vitro by short RNAs (3).
These studies suggest that the kissing-loop complex
formed by SL1 could be a potential target for anti-HIV-1
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doi:10.1093/nar/gkl317Figure 1. TheHIV-1DISandaminoglycosides.(a)LocationoftheDISinthe50-untranslatedregion(50-UTR)ofthegenomicRNA.(b)PhylogenyoftheDISloop.
(c) Mechanism of dimerization. (d) Similitude between the DIS kissing-loop complex and the bacterial ribosomal A site. Nucleotides that are identical in the two
RNAs are in boldface; those that are required for binding of aminoglycoside antibiotics to the ribosomal A site are indicated in bold italic. (e) 4,5-disubstituted and
(f) 4,6-disubstituted DOS derivatives used in this study. The common DOS ring is colored in red. Note that neamine is a monosubstituted DOS.
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molecules, we studied the selective targeting of the SL1
kissing-loop complex by aminoglycosides (Figure 1e and f).
Indeed, the secondary and tertiary structures of the DIS
kissing-loop complex present an unexpected strong similitude
with the bacterial ribosomal A site (Figure 1d), and a prelimi-
nary study showed that some, but not all, aminoglycoside
antibiotics that bind to the ribosomal A site also bind to the
DIS (16). Here, we present high-resolution X-ray structures
of four aminoglycosides bound to the DIS kissing-loop com-
plex. They demonstrate speciﬁc binding of neamine and
4,5-disubstituted 2-deoxystreptamine (DOS) to the DIS and
provide the basis for rational design of ligands with improved
properties. In addition, we were able to demonstrate that
some of these aminoglycosides are able to target the DIS
in the context of the genomic RNA in infected cells and in
virions and that they prevent dissociation of the kissing-loop
complex in vitro.
MATERIALS AND METHODS
Crystallization of DIS/aminoglycoside complexes
A 23mer RNA corresponding to the subtype F DIS was pur-
chased from Dharmacon (Boulder, CO) and puriﬁed as
described (17). For structure solving, a 5-bromo-uridine
was substituted for uridine 3 of the 23mer RNA. RNA was
heated in water at 90 C for 3 min and chilled on ice for
10 min. Buffer was then added to reach a ﬁnal concentration
of 150 mM KCl, 5 mM MgCl2 and 20 mM sodium cacodylate
(pH 7.0). RNA was then concentrated on a Centricon 10 K
(Millipore) to a ﬁnal concentration of 300–360 mM. All
aminoglycosides were obtained from Sigma and used without
puriﬁcation, except neamine, which was obtained from neo-
mycin by acidic treatment as described (18). Crystals of
aminoglycoside/DIS complexes were obtained by mixing
7 ml of the RNA solution with 1.8 ml of a solution containing
5 mM neamine chloride or ribostamycin sulfate in 30% (w/v)
2,4 methylpentanediol (MPD) or with 1.0 ml of a solution
containing 5 mM neomycin sulfate or 5 mM lividomycin sul-
fate in 30% MPD. Sitting drops were equilibrated over 2 days
at 37 C against a reservoir containing 40% MPD, 300 mM
KCl, 50 mM sodium cacodylate (pH 7.0), 20 mM MgCl2
and crystals were transferred at 20 C for stabilization.
Crystals were frozen in liquid ethane prior to data collection.
X-ray data collection, structure solution and refinement
Data were collected at 100 or 120 K on ID23-1 and ID-29 at
the ESRF (Grenoble, France) or on X06SA at the SLS
(Villigen, Switzerland) (Table 1 and Supplementary Table
S1) and processed with the HKL package (19). The two
bromide sites of the neamine–DIS complex were located
with CNS (20) using the anomalous signal. The structure
was solved with CNS by MAD using a three wavelength
experiment (Supplementary Table S1), followed by solvent
ﬂattening with 50% solvent content. This structure was then
used to solve the ribostamycin–DIS complex by molecular
replacement using CNS with PC reﬁnement, and the
neomycin–DIS complex using Molrep (21) with advanced
rotation function and translation function options. The
lividomycin–DIS complex was solved by rigid body reﬁne-
ment of the neomycin–DIS complex. Molecular replacement
attempts using unbound DIS kissing-loop complexes all
remained unsuccessful. All structures were reﬁned with
CNS. Potassium sites were localized by anomalous difference
maps using datasets of the neomycin–DIS and ribostamycin–
DIS complexes collected at 1.5 or 1.65 s wavelengths (Sup-
plementary Table S1) to maximize the anomalous signal
of the potassium (f00 ¼ 1.01  e e). Occupancy of bromide in
bromo-uridines was not set to 1.0 and reﬁned due to strong
radiolysis during data collection (22).
In vitro footprinting of aminoglycosides
Chemical footprinting experiments were performed on a
23mer subtype A SL1 RNA or on RNA1-615, which corre-
sponds to nucleotides 1–615 of HIV-1 Mal genomic RNA,
as described previously (16). Chemical modiﬁcation was
carried out either with dimethyl sulfate (DMS, Fluka) to
test the accessibility of N1-A and N3-C positions or with
lead acetate (Merck), which selectivity cleaves the subtype
A DIS loop between the ﬁrst and second nucleotides.
Infectious HIV-1 molecular clones, cell culture,
transfections and infections
The HIV-1 NL4.3 molecular clone was used to generate mut-
ant constructs with 272–280 nt (DIS loop) from the subtype A
and F isolates substituted for the homologous NL4.3 region.
To obtain these constructs, the QuickChange  site-directed
mutagenesis kit was used according to the manufacturer
(Stratagene), using plasmid DNA pLTR50-NL4.3 (4). The
resulting mutant plasmids were digested with AatII and
SphI and the AatII–SphI fragment was substituted for the
homologous region of pNL4.3. Mutations were conﬁrmed
by DNA sequencing.
HeLa cell cultures and transfections were performed as
described previously (23). Viral replication of wild-type
Table 1. Data collection and refinement statistics
Neamine
a Ribostamycin Neomycin Lividomycin
a
PDB ID 2FCX 2FCZ 2FCY 2FD0
Space group C2221 C2 C2221 C2221
a( A ˚) 27.0 112.1 27.2 27.1
b( A ˚) 113.4 27.2 117.8 115.3
c( A ˚) 95.0 106.9 94.6 95.3
b 90  116.7  90  90 
Beamline X06SA X06SA X06SA X06SA
Wavelength (A ˚) 0.91961 0.91946 0.91946 0.91946
Resolution
range (A ˚)
40–2.0 20–2.0 40–2.2 40–1.8
Average
redundancy
6.8 3.3 4.3 6.3
Unique reflexions 18 852 18 764 7689 26 564
Completeness
b 98.6 (92.7) 95.4 (99.2) 96.7 (90.2) 99.3 (98.7)
Rsym
b 7.4 (27.3) 6.3 (25.6) 5.9 (23.1) 6.1 (27.3)
Average I/s
b 24.4 (4.0) 18.9 (5.7) 20.7 (6.4) 26.4 (3.5)
R/Rfree 26.7/29.2 23.8/25.6 23.5/25.3 24.5/24.5
Water molecules 35 208 74 90
Cations 3 K
+ 4K
+ 6K
+ 4K
+
Anions 1 Cl
  01 C l
 ,1S O 4
2  1C l
 
Aminoglycosides 2 4 2 2
aFriedel mates were processed separately.
bValues for last resolution shell are shown in parenthesis.
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in the culture supernatant of infected H9 cells.
Aminoglycoside footprinting on the HIV-1 genomic
RNA in infected cells and virions
To detect the footprint of aminoglycosides on the DIS of the
HIV-1 genomic RNA, ﬁve millions CEM · 174 cells were
infected with equivalent amount of wild-type and mutant
viruses as determined by RT activity. One hour after infec-
tion, cells were diluted in 20 ml RPMI 1640 [supple-
mented with 10% heat-inactivated fetal calf serum (FCS)]
and cultured in the absence or in the presence of 3 mM
aminoglycosides.
At 72 h after infection, CEM · 174 cells were washed
twice with phosphate-buffered saline (1· PBS) and sus-
pended in 30 mlo f1 · PBS. Progeny viruses were collected
and puriﬁed as described (23). Cells and viruses were treated
with 3 ml of DMS for 4 and 8 min at 37 C. Reaction was
stopped by adding 1 ml of TriReagent (Molecular Research
Center), and RNA was extracted as described by the supplier.
Modiﬁed bases were detected by primer extension as
described (24).
Stabilization of the kissing-loop complex by
aminoglycosides
In a typical experiment, unlabeled 1–615 RNA (400 nM),
together with a corresponding internally labeled RNA
(3–5 nCi), were heated for 2 min at 90 C, chilled for 2 min
on ice and dimerization was initiated by addition of 2 mlo f
5-fold concentrated dimerization buffer [ﬁnal concentration:
50 mM sodium cacodylate (pH 7.5), 300 mM KCl, 5 mM
MgCl2]. After incubation at 37 C for 20 min, 100 mMo f
aminoglycosides were added to the RNA mixture and sam-
ples were further incubated for 15 min. Then, RNA 1–311
was added as a competitor and samples were collected at 2,
5, 10, 15, 20, 30 and 60 min and analyzed on 0.8% agarose
gels [45 mM Tris–borate (pH 8.3), 01 mM MgCl2]a t4  C.
Gels were ﬁxed in TCA 10%, dried, and analyzed using a
BAS 2000 Bio-Imager (Fuji).
RESULTS
Crystal structures of the DIS/aminoglycoside complexes
In view of our previous results (16), we attempted to
co-crystallize a 23mer RNA corresponding to the subtype
F DIS with neamine and several 4,5-disubstituted and
4,6-disubstituted DOS derivatives (Figure 1e and f). We
obtained co-crystals with neamine, ribostamycin, neomycin
and lividomycin and the structures of these four complexes
were solved at 1.8–2.2 s resolution (Table 1). These struc-
tures are very similar and mainly differ by the size of the lig-
and. In all complexes, two aminoglycosides interact with the
two (A-site)-like motifs of the loop–loop complex (Figure 2a
and b). The average distance separating the two aminoglyco-
sides is 4.4 s, whereas the prediction from our previous
model was 5.6 s. RNA conformational change following
ligand binding is restricted to a ribose pucker shift of G271
from C20-endo in most free structures (25) to C30-endo con-
formation in present structures (Supplementary Figure S1).
This movement induces an opening of the aminoglycoside
pocket, avoiding a steric conﬂict between cycle I of the
aminoglycosides and G271 phosphate and ribose.
We recently solved the structure of an unliganded form of
the subtype F kissing-loop complex in which the ribose
pucker of G271 is C30-endo (26). This structure is also charac-
terized by a continuous stacking of the four bulged out
purines (two in each RNA molecule) of the kissing-loop
complex, contrasting with the two pairs of stacked purines
separated by a gap observed in most DIS kissing-loop
complexes (26). Superimposition of the structures shows
that binding of 4,5-disubstituted DOS to this conformation
of the kissing-loop complex also requires a structural rear-
rangement of the binding pocket to prevent a steric clash
with phosphate 272, suggesting that aminoglycoside binding
is incompatible with continuous stacking of the four bulged
out purines (data not shown).
Aminoglycoside binding in the DIS pocket results in the
displacement of the hexahydrated magnesium, bound to the
50-UGCA-30 sequence of the intermolecular helix of the unli-
ganded kissing-loop complex, that is required for dimeriza-
tion of non subtype B DIS. This displacement is obligatory
because the two axial water molecules bound to O4 of U275
and to the magnesium are replaced by the two positively
charged N1 amino groups of each DOS ring (Supplementary
Figure S1). This likely explains why magnesium is dispens-
able for DIS dimerization in presence of aminoglycosides
(data not shown).
Each aminoglycoside molecule interacts simultaneously
with both RNA molecules of the loop–loop helix. Interactions
are either direct, or mediated by conserved water molecules
or cations (Figure 2c,d and Figure 3 and Supplementary
Figure S2). Ring II (the DOS ring) almost exclusively inter-
acts with one RNA molecule (in blue in Figure 2c,d and
Figure 3), while rings I, III and IV bind only to the other
RNA molecule (in green in Figure 2c,d and Figure 3). A
total of 15 direct antibiotic-RNA contacts are observed for
the neomycin–DIS complex (Figure 3), i.e. more than in
the equivalent paromomycin–ribosomal A site complex,
which is stabilized by 11 direct contacts. Analysis of these
contacts reveals that, as for the A site, rings I, II and III are
responsible for the sequence and structure speciﬁcity of
aminoglycoside binding: base-speciﬁc contacts involve
residues G271,A 278,C 279,G 274 and U275, as well as A280
which forms a Watson–Crick-like base pair with ring I
(Figure 3). Many of these contacts were also observed
between this ‘ribostamycin core’ and the ribosomal A site.
This is not surprising, given the remarkable similitude of
the two complexes (Figure 4). However, some contacts are
speciﬁc for the DIS–4,5-disubstituted DOS complexes: e.g.
with the A278 of the U275–A278 base pair replacing U1406 in
the universal U1406–U1495 mismatch in the ribosomal 18S
RNA (Figure 1d). More interesting are the two phosphates
of the bulged-out A1492 and A1493 of the ribosomal RNA
that make direct contacts with O30 and O40 of ring I
(27,28). Because of the difference in topology between the
two RNA structures (loop–loop complex versus duplex),
these phosphates are displaced in the DIS compared to the
ribosomal A site (Figure 4). In spite of this difference, ring
I is able to strongly bind to the loop–loop backbone owing
to four direct interactions involving O40,O 3 0 and N20 with
Nucleic Acids Research, 2006, Vol. 34, No. 8 2331Figure 2. Structure of the ribostamycin/DIS complex. (a and b): two stereo views of the ribostamycin–DIS complex rotated by 90 . The two RNA molecules are
represented in light and dark grey and the two aminoglycosides in red and orange. The 2Fo-Fc electron density map contoured at 1.4 s level is represented in green
aroundtheRNAandinbluearoundaminoglycosides.Forthesakeofclarity,watermoleculesandionsarenotrepresented.(candd):detailsoftheDIS–ribostamycin
complex.ThetwoRNAstrandsarerepresentedingreenandblue.Potassiumcationsandwatermoleculesarerepresentedasyellowandredspheres,respectively.The
2Fo-Fc electron density map contoured at 1.4 s level is represented around the refined model.
2332 Nucleic Acids Research, 2006, Vol. 34, No. 8the phosphate moiety of A272 and A273 (Figure 2c,d and
Figure 3). In addition, the high quality of the electron density
maps allowed the observation of a complex network of well-
deﬁned water molecules reinforcing the drug–RNA interac-
tion. Water bridges were also observed between the two
aminoglycoside molecules within a loop–loop complex
(Figure 3 and Supplementary Figure S2). Also interesting, a
conserved potassium cation was observed at the drug–RNA
interface, where it mediates contacts between ring I and the
phosphate group of A272 and A273 (Figure 2c,d and
Figure 3 and Supplementary Figure S2). This peculiar mode
of potassium binding is present neither in the unliganded DIS
loop–loop complex, nor in the aminoglycoside/ribosomal A
site complexes. Thus, this is a speciﬁc feature of the DIS–
aminoglycoside complexes. As the O30 hydroxyl group is
lacking in lividomycin (Figure 1e), the potassium ion is not
present in the DIS–lividomycin complex (Supplementary
Figure S2), and direct contacts involving this position are
also lost.
At variance with the ‘ribostamycin core’, rings IV and V
bind more loosely to the DIS and are exclusively involved
into non-speciﬁc interactions with the RNA backbone.
These rings adopt several conformations in the RNA deep
groove, and they are characterized by high temperature fac-
tors, contrasting with the very low temperature factors of
rings I and II and the surrounding RNA. As a consequence,
the density for ring V, and also to some extent for ring IV,
is poor (Supplementary Figure S2), as also observed in the
complexes with the ribosomal A site (28,29). This ﬂexibility
is conﬁrmed by a superimposition of rings I and II of
paromomycin bound to the ribosomal A site (28) to the
aminoglycosides observed in the present structures
Figure3.Schematicdrawingsummarizingallneomycin–RNAcontacts.Contactsunderlinedinpinkwerenotpresentintheequivalentaminoglycoside-ribosomalA
sitestructure.‘w’and‘K
+’spheresrepresentwatermoleculesandapotassiumcation,respectively.ThetwoRNAstrandsofthekissing-loopcomplexarerepresented
and annotated in blue and in green.
Nucleic Acids Research, 2006, Vol. 34, No. 8 2333(Figure 4). Rings I, II and III adopt a unique conformation
in all structures, whereas rings IV and V (by comparing the
two molecules in the asymmetric unit) can adopt different
orientations.
In vitro binding of aminoglycoside antibiotics to the DIS
Even though a number of 4,5-disubstituted and 4,6-
disubstituted DOS derivatives were tested, we only obtained
co-crystals of the DIS kissing-loop complex with neamine
and 4,5-disubstituted compounds. Indeed, all our attempts
at co-crystallizing 23mer SL1 RNA with tobramycin or
kanamycin B, two 4,6-disubstituted DOS (Figure 1f), resul-
ted in crystals containing only the RNA. Modeling of
4,6-disubstituted compounds in the kissing-loop complex
based on the structural analogy with the ribosomal A site
and the structure of this site with tobramycin and gentamicin,
suggests that these compounds would clash with positions N4
of C277 and N6 of A278 in the kissing-loop complex, where it
differs from the ribosomal A site (Supplementary Figure S3).
However, minor changes in the RNA structure would be
sufﬁcient to allow binding of 4,6-disubstituted DOS to the
kissing-loop complex.
At this stage, it was unclear if this class of compound is
able to bind to the DIS kissing-loop complex. Therefore, to
compare binding of 4,5-disubstituted and 4,6-disubstituted
DOS, we let a 23mer RNA corresponding to the subtype-A
DIS form the kissing-loop complex. As shown previously,
lead (II) induced a speciﬁc cleavage in the subtype A DIS
loop that is sensitive to the binding of aminoglycoside
(Figure 5a). Remarkably, none of the 4,6-disubstituted DOS
we tested inhibited this cleavage at 100 mM, suggesting that
they did not bind to the kissing-loop complex. Among the
4,5-disubstituted DOS, neomycin, paromomycin and livido-
mycin completely inhibited lead-induced cleavage of the sub-
type A DIS loop at 25 mM, whereas ribostamycin was less
efﬁcient (Figure 5a and data not shown). Unexpectedly, the
bicyclic neamine inhibited cleavage at lower concentration
than the tricyclic ribostamycin (Figure 5a). Neamine has
also a higher afﬁnity than ribostamycin for the ribosomal
A site (30), but neither the crystal structures of these
aminoglycosides with the DIS kissing-loop complex (this
study) nor those with the ribosomal A site (29) provide a
clear explanation for these observations.
In order to evaluate the capacity of neamine and
4,5-disubstituted DOS to bind to the DIS kissing-loop com-
plex in a larger RNA presenting numerous unspeciﬁc binding
sites, we used RNA1–615, which corresponds to nucleotides
1–615 of the HIV-1 MAL genomic RNA. This recombinant
isolate possesses a subtype A DIS. Using a primer extension
assay, we found that the lead-induced cleavage between
nucleotides A272 and G273 (in this isolate, the DIS loop
corresponds to nucleotides 272–280; see Figure 1c) was
almost completely inhibited at 50 mM neomycin and
lividomycin (Figure 5b). Similar results were obtained with
paromomycin (data not shown). However, no inhibition was
observed with neamine and ribostamycin, even at 100 mM
(Figure 5b).
To conﬁrm these results, we used DMS footprinting
(Figure 5c). Residues A272 and A280 of RNA1–615 are
unpaired in the kissing-loop complex and are methylated by
DMS at their N1 position. As observed previously (13,31),
Figure 4. (a) Superimposition of the ribosomal A site–paromomycin complex (grey) with the DIS–neomycin complex (neomycin is in red and the two RNA
molecules in blue and green). (b) Superimposition of paromomycin in the A site (grey) with neamine (blue), ribostamycin (yellow), neomycin (orange) and
lividomycin(red)boundtotheDISloop–loopcomplex.RingsItoIVarelabeled,whereasringVoflividomycin,whichpointstowardsthereader,isnot.Ther.m.s.d.
for rings I and II ranges from 0.08 to 0.25 s.
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otide is ﬂipped out of the helix, while the former is stacked
inside the structure. At 10 mM and above, neomycin and
lividomycin strongly protected A280 against methylation
(Figure 5c). This result was predictable in light of the
pseudo-Watson–Crick interaction between this base and
ring I of 4,5-disubstituted DOS (Figure 3). On the other
hand, A272, which is ﬂipped out of the kissing-loop complex
was not protected against methylation by DMS (Figure 5c).
Importantly, A280 was the sole nucleotide to be protected
against methylation by neomycin and lividomycin in the
region covered by the primer used in this study
(150–350 nt). As for the lead-induced cleavage, neamine
and ribostamycin provided no protection against methy-
lation, even at 100 mM (Figure 5c). Thus, even though
these compounds bound to short DIS RNA in the same
way as neomycin and lividomycin (Figure 4), they
were unable to efﬁciently recognize this target in the
context of a large RNA containing numerous unspeciﬁc
binding sites.
Using DMS footprinting, we found that neomycin, paro-
momycin and lividomycin also efﬁciently bound to the sub-
type F kissing-loop complex in the context of RNA1–615,
while neamine and ribostamycin did not (data not shown).
In addition, in line with our previous study (16), none of
the 4,5-disubstituted DOS bound to the subtype B
kissing-loop complex (data not shown).
Stabilization of the kissing-loop complex by
4,5-disubstituted DOS
Preliminary studies on a short RNA strongly suggested that
aminoglycosides increase the thermal stability of the DIS
kissing-loop complex (16). Here, we directly studied the
Figure 5. In vitro binding of aminoglycosides to subtype F and subtype A DIS. (a) Inhibition of the lead (II)-induced cleavage of a 23mer subtype F DIS RNA by
aminoglycosides. Nea, Ribo, Neo, Paro, Livi, Tobra, Kana, Genta stand for neamine, ribostamycin, paromomycin, lividomycin, tobramycin, kanamycin and
gentamicin, respectively. Numbers correspond to mM concentration of the aminoglycoside.  Pb and +Pb correspond to control lanes without aminoglycoside,
without and with lead acetate, respectively. (b) Inhibition of lead-induced cleavage of MAL RNA1–615. Lanes 1–4 correspond to 0, 10, 50 and 100 mM
aminoglycoside. ( ) corresponds to an extension control performed in the absence of lead acetate. (c) DMS footprinting of aminoglycosides on MAL
RNA1–615. Aminoglycoside concentrations and control lanes are as in (b). In (b and c), lanes U, A, C and G correspond to dideoxy sequencing reactions, which
allowedtolocalizethelead-inducedcutandmethylatedadenines,respectively.(d)Stabilizationofthekissing-loopcomplexby4,5-disubstitutedDOS.Radiolabeled
RNA 1–615 was incubated in dimerization buffer, and unlabeled RNA1–311 was added to the solution in absence or in presence of aminoglycoside, as indicated
above the gel. Lane C, control dimer without aminoglycoside. d, m and h stand for dimer, monomer and heterodimer, respectively.
Nucleic Acids Research, 2006, Vol. 34, No. 8 2335effects of aminoglycosides on the dynamics of the
kissing-loop complex at 37 C, in the context of RNA1-615
(Figure 5d).
We formed the kissing-loop complex of radiolabeled
RNA1–615, then added aminoglycosides at a 100 mM
concentration. Next, we added a 5-fold excess of unlabeled
RNA1–311, encompassing 1–311 nt of HIV-1 MAL geno-
mic RNA, that also contains the subtype A DIS and is thus
able to form a heterodimer with RNA1–615 (Figure 5d).
Due to the dynamic nature of the kissing-loop complex, in
the absence of aminoglycoside, more than half of the radio-
active material was shifted in the heterodimer within 2 min,
and the RNA1–615 homodimer almost completely disap-
peared upon prolonged incubation. Similar results were
obtained in the presence of 100 mM neamine and ribo-
stamycin (Figure 5d). However, only minimal amounts of
heterodimer were formed after 1 h when 100 mM neomycin,
paromomycin or lividomycin were present in the reaction,
and the amount of RNA1–615 homodimer remained
almost constant (Figure 5d and data not shown). This obser-
vation demonstrates that 4,5-disubstituted DOS that efﬁ-
ciently bound to the DIS dramatically reduced dissociation
of the kissing-loop complex. This observation is in keeping
with our crystal structures showing that 4,5-disubstituted
DOS form a bridge between the two RNA molecules
(Figure 3).
Binding of aminoglycoside antibiotics to the DIS in
infected cells and virions
The next step was to test if 4,5-disubstituted DOS are able to
target the DIS in the context of the complete HIV-1 genomic
RNA, in infected cells or in viral particles. We recently
showed that it is possible to monitor modiﬁcation of the
HIV-1 genomic RNA by DMS in cells and in viral particles
(23,24). Here, we used this technique to detect binding of
4,5-disubstituted DOS to the DIS ex vivo. To the best of
our knowledge, this is the ﬁrst example of footprinting of a
small RNA ligand in cells or virions.
As all generally used HIV-1 laboratory strains are subtype
B strains, we substituted subtype A or subtype F DIS loop
sequences for the original subtype B DIS loop in the
pNL4.3 infectious molecular clone. These substitutions did
not affect replication of the mutant viruses (Supplementary
Figure S4). As previously observed in vitro, in the absence
of aminoglycoside, A280 was more reactive in cells and viri-
ons than A272 (Figure 6a). Adding neomycin, paromomycin
or livodomycin to the culture medium did not completely
protect A280 from methylation by DMS, but the intensity of
the band decreased, reﬂecting partial protection. In order to
quantify this protection, we normalized modiﬁcation of
A280 relative to A272, thus correcting the intensity of
the bands for variations in the amount of material used in
Figure 6. Aminoglycoside-induced DIS protection in CEM · 174 cells and in virions. (a) Methylation of the genomic RNA in infected cells and in virions was
performedaccordingtothe‘MaterialsandMethods’section.Lane( ),extensioncontrolwithoutDMS;laneC,DMStreatmentwithoutaminoglycoside;lanesL,N
andP:DMStreatmentinthepresenceoflividomycin,neomycinandparomomycin,respectively.Sequencelanes(U,A,CandG)wereruninparalleltoidentifythe
modifiednucleotides.(b)ThegelsshowninAwerequantifiedandmodificationofA280,normalizedtothatofA272,wascomparedtothatobtainedintheabsenceof
aminoglycoside (which was arbitrarily set to 1 for each HIV-1 subtype).
2336 Nucleic Acids Research, 2006, Vol. 34, No. 8the primer extension assay. The inﬂuence of aminoglycosides
on the relative modiﬁcation of A280 is shown in Figure 6b.
Paromomycin, neomycin and lividomycin did not protect
A280 against methylation of subtype B DIS in infected cells
and in viral particles. However, these three 4,5-disubstituted
DOS reduced alkylation of the subtype A and subtype F DIS
more than 2-fold. Subtype A and subtype F DIS were
protected to the same extent in cells, while protection of sub-
type F DIS was systematically more efﬁcient in virions
(Figure 6b). The origin of this difference is unknown.
Notably, paromomycin, neomycin and lividomycin provided
similar levels of protection. As already noticed in our in vitro
experiments, A280 was the sole nucleotide to be protected
against DMS by paromomycin, neomycin and lividomycin
in cells and virions in the region we analyzed (150–350 nt).
DISCUSSION
Despite the efﬁciency of highly active antiretroviral therapy,
the emergence of resistant strains and the side effects of the
current treatments highlight the need for new inhibitors of
HIV-1 replication. In addition to viral and cellular proteins,
the genomic RNA itself has been proposed as a drug target
(32). For instance, molecules targeting the trans activating
region (TAR) (33–35), the packaging signal (36,37), the
frameshifting signal (38) and the rev responsive element
(RRE) (39,40) have been selected in vitro. Aminoglycosides
have been shown to bind to several of these sites
(34,36,37,39,40), but in most cases, the selectivity and speci-
ﬁcity of binding were not addressed or poorly understood.
We took advantage of the structural similitude we identi-
ﬁed between the crystal structures of the bacterial ribosomal
A site and the HIV-1 kissing-loop complex (16) to target the
DIS with aminoglycosides that are known to speciﬁcally
interact with the bacterial A site. Indeed, binding of amino-
glycosides to the kissing-loop complex could be predicted
from its crystal structure, characterized by the ﬁrst two
purines of the DIS loop bulging out (25), but not from its
NMR structures (41,42), in which one or two of these purines
are buried in the structure. The crystal structures of
the DIS–aminoglycoside complexes we report here conﬁrm
the strong similitude of the kissing-loop complex with the
ribosomal A site, and support the biological relevance of
the ﬂipped out conformation of the ﬁrst two purines of the
DIS loop. Strangely enough, several contacts are speciﬁc
for the kissing-loop complex, and 4,5-disubstituted DOS
build more direct interactions with the kissing-loop complex
than with the A site.
Interestingly, our crystal structures and biochemical
experiments revealed that binding of aminoglycosides to the
DIS is speciﬁc regarding both the aminoglycoside family
and the RNA subtype. In contrast with neamine and
4,5-disubstituted DOS, 4,6-disubstituted DOS, which also
bind to the bacterial ribosomal A site, do not speciﬁcally
bind to the HIV-1 kissing-loop complex. Our crystal struc-
tures combined with modeling strongly suggest that residue
A278 prevents binding of 4,6-disubstituted DOS to the
kissing-loop complex. Indeed, the structurally equivalent
position in the ribosomal A site is U1406 (Figure 1d), and it
has been shown that substituting an A for U1406 in the
16 ribosomal RNA confers resistance to 4,6-disubstituted
DOS, but not to 4,5-disubstituted DOS (43,44).
Neamine and 4,5-disubstituted DOS bind to subtype A and
subtype F, but not to subtype B DIS. Our X-ray structures
of the subtype F DIS complexed with neamine and
4,5-disubstituted DOS demonstrate that this subtype speciﬁ-
city is linked to the identity of the second nucleotide in the
DIS self-complementary sequence. This nucleotide is a
uridine (U275) in all HIV-1 subtypes, except in subtypes B
and D (Figure 1b). The corresponding nucleotide in the bac-
terial ribosomal A site is also a uridine (U1495) (Figure 1d). In
the complexes involving the subtype F DIS and neamine or
4,5-disubstituted DOS, atom O4 of U275 makes a hydrogen
bond with the amino group at position 1 of ring II of the
aminoglycoside (Figure 3). In the subtype B kissing-loop
complex, the amino group at position 4 of C275 would clash
with the aminoglycoside amino group, thus preventing bind-
ing. In line with this interpretation, substituting a C or an A,
but not a G, for U1495 in the Escherichia coli A site RNA pre-
vents paromomycin binding (45), whereas substituting a C
residue for U1495 in Mycobacterium smegmatis 16S RNA
confers resistance to both 4,5-disubstituted and 4,6-
disubstituted aminoglycosides (43). Interestingly, our crystal
structures indicate that substituting a hydroxyl for the amino
group at position 1 of ring II of 4,5-disubstituted DOS should
allow to target subtype B HIV-1 strains.
Even though this has not been experimentally tested, our
structures predict that 4,5-disubstituted DOS should not
bind to the kissing-loop complex of HIV-1 strains belonging
to subtype C of group M (main) and to group O (outlier). In
these strains, A280, which forms a pseudo Watson–Crick base
pair with the aminoglycoside ring I (Figure 3), is replaced by
a uridine or a cytosine, respectively (Figure 1b). If these resi-
dues are unpaired and stacked inside the structure, as A280 in
the kissing-loop structure of subtypes A&G, B&D and F&H,
it should be possible to modify ring I in order to speciﬁcally
target these strains. However, in these strains, nt A280 can
potentially form a Watson–Crick base pair with residue
272, reducing the DIS loop to 7 nt. If this base pair does
form, it would be impossible to target the corresponding
kissing-loop complexes with 4,5-disubstituted aminoglyco-
sides. Thus, it would be interesting to solve the structure of
these kissing-loop complexes.
The selectivity of binding with respect to the aminoglyco-
side family and to the HIV-1 subtype clearly show that bind-
ing of neamine and 4,5-disubstituted DOS to the HIV-1
kissing-loop complex does not only rely on non speciﬁc elec-
trostatic interactions, but also on speciﬁc contacts. Our crystal
structures clearly indicate that the binding speciﬁcity is
mainly driven by rings I and II, and to a lesser extend by
ring III of 4,5-disubstituted DOS, which interact with the
RNA bases and the particular sugar-phosphate backbone
motif of the kissing-loop complex. At the opposite, rings
IV and V mainly contribute to binding by interacting with
phosphate groups in a regular A type conformation. However,
our biochemical experiments demonstrate that these interac-
tions are essential to target the DIS when multiple non-
speciﬁc targets are also present.
Indeed, our in situ footprinting experiments demonstrated
that 4,5-disubstituted DOS with four or ﬁve rings are able
to target the DIS in infected cells and in virions. These
Nucleic Acids Research, 2006, Vol. 34, No. 8 2337experiments demonstrate that the DIS is accessible in vivo,
a prerequisite for a drug target. This is the ﬁrst demonstration
that aminoglycosides speciﬁcally bind to HIV-1 genomic
RNA in cell culture, and to the best of our knowledge, the
only direct demonstration that a small ligand directed against
HIV-1 RNA does bind to its predicted target in infected cells
and/or in viral particles.
Binding of 4,5-disubstituted DOS to the DIS appears to
stabilize the kissing-loop complex. This is not surprising
since these compounds were predicted to bind to the
kissing-loop complex rather than to the monomeric form
of the DIS. At odds with our results, neomycin and
paromomycin were also reported to bind to the subtype B
DIS loop under ionic conditions in which the monomeric
form of HIV-1 RNA prevails (36,37). However, as these
experiments were conducted at very low ionic strength and
in the absence of multivalent cations, this binding was most
likely driven by unspeciﬁc electrostatic interactions, in keep-
ing with the numerous binding sites observed in the HIV-1
packaging signal under these conditions (36,37). In line
with this interpretation, our in vitro and in situ DMS foot-
printing experiments identiﬁed the DIS as the only speciﬁc
aminoglycoside binding site between 150 and 350 nt.
Our study demonstrates that aminoglycosides can speciﬁc-
ally target the DIS of the HIV-1 genomic RNA in cells and
in virions. The next step would be to achieve inhibition of
HIV-1 replication. Analysis of the effects of aminoglycosides
on HIV-1 molecular clones harboring either a subtype B, a
subtype A or a subtype F DIS did not show any signiﬁcant
inhibition that could be correlated to binding of these com-
pounds to the DIS (J.-C. Paillart and R. Marquet, unpublished
data). The lack of inhibition might be due to incomplete sat-
uration of the DIS by aminoglycosides in cells and virions, as
indicated by the partial protection of A280 against methyla-
tion, which is most likely the result of the poor penetration
of aminoglycosides in eukaryotic cells. Alternatively, target-
ing and stabilizing the DIS is not sufﬁcient to inhibit HIV-1
replication. Hopefully, our high-resolution structures of DIS–
aminoglycoside complexes provide us with the necessary
basis to identify aminoglycoside mimics with simpler chem-
istry and improved biodisponibility that would make similar
interactions with the kissing-loop complex. They should
also reveal invaluable for the rational design of derivatized
molecules that would irreversibly cleave, crosslink or modify
the viral RNA after binding to the DIS.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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